The treatments for DM1 with tideglusib are directly connected to the core mechanisms of DM1, in which the toxic CUG-containing RNA affects RNA-binding protein, CUGBP1, by converting active CUGBP1 into CUGBP1 repressor. Here, CELF1 is linked to myotonic dystrophy type 1.